Genetic adjuvants: A paradigm shift in vaccine development and immune modulation

Area of Science:

• Vaccinology and Immunology
• Molecular Biology
• Infectious Disease Research

Background:

• The COVID-19 pandemic highlighted the need for effective vaccines, particularly for vulnerable groups.
• Recombinant protein vaccines are safe but often lack immunogenicity, necessitating advanced platforms.
• Genetic vaccines (DNA, mRNA) show promise but require novel adjuvants due to differing mechanisms.

Purpose of the Study:

• To explore the potential of genetically encoded adjuvants in enhancing vaccine efficacy.
• To compare genetic adjuvants with traditional formulations and their integration with new technologies.
• To discuss the mechanisms and delivery optimization of genetic adjuvants for next-generation vaccines.

Main Methods:

• Review of preclinical and clinical studies on genetic/nucleic acid vaccines and adjuvants.
• Analysis of immune pathways targeted by genetic adjuvants, including antigen presentation and T cell activation.
• Comparative assessment of genetic adjuvants against traditional vaccine adjuvants.

Main Results:

• Genetic adjuvants, encoded within DNA, RNA, or viral vectors, show potential for improving vaccine immunogenicity.
• These adjuvants fine-tune innate and adaptive immunity, addressing challenges like immune senescence and CD8+ T cell activation.
• Genetic adjuvants offer a promising approach to overcome limitations of current vaccine technologies.

Conclusions:

• Genetically encoded adjuvants represent a significant advancement in vaccine development.
• Optimizing the mechanisms and delivery of genetic adjuvants is key to next-generation immunization.
• These adjuvants hold promise for enhancing vaccine effectiveness in diverse populations and against various infectious diseases.